Indeed, a siRNA-mediated SEC62 knock-down in vitro led to a highly effective inhibition of cancer cell migration in HNSCC, NSCLC, prostate cancer, and cervical cancer cells (Greiner et al., 2011; Linxweiler et al., 2012, 2016; Bochen et al., 2017). Here, SEC62 is linked to cervical carcinoma.